Tolerability of solifenacin and oxybutynin immediate release in older (>65 years) and younger (≤65 years) patients with overactive bladder: sub-analysis from a Canadian, randomized, double-blind study

Author： Herschorn S.   Pommerville P.   Stothers L.   Egerdie B.   Gajewski J.   Carlson K.   Radomski S.   Drutz H.   Schulz J.   Barkin J.   Hirshberg E.   Corcos J.  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.27, Iss.2, 2011-02, pp. : 375-382

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study

By Hill Simon   Elhilali Mostafa   Millard Richard J   Dwyer Peter L   Lheritier Karine   Kawakami Fernando T.   Steel Michael  

Current Medical Research and Opinion, Vol. 23, Iss. 11, 2007-11 ,pp. : 2697-2704

Informa Healthcare

Access to resources Recommend Favorite

Cost-effectiveness analysis of solifenacin versus oxybutynin immediate-release in the treatment of patients with overactive bladder in the United Kingdom

By Hart Warren Mark   Abrams Paul   Munro Vicki   Retsa Peny   Nazir Jameel  

Journal of Medical Economics, Vol. 16, Iss. 10, 2013-10 ,pp. : 1246-1254

Informa Healthcare

Access to resources Recommend Favorite

Optimum Dose of Once‐Daily Oxybutynin Patch in Japanese Patients with Overactive Bladder: A Randomized Double‐Blind Trial Versus Placebo

By  

LUTS, Vol. 8, Iss. 3, 2016-09 ,pp. : 150-158

John Wiley & Sons Inc

Access to resources Recommend Favorite

Darifenacin treatment of patients ≥ 65 years with overactive bladder: results of a randomized, controlled, 12-week trial

By Chapple C   DuBeau C   Ebinger U   Rekeda L   Viegas A  

Current Medical Research and Opinion, Vol. 23, Iss. 10, 2007-10 ,pp. : 2347-2358

Informa Healthcare

Access to resources Recommend Favorite

Factors associated with dose escalation of fesoterodine for treatment of overactive bladder in people >65 years of age: A post hoc analysis of data from the SOFIA study

By  

NEUROUROLOGY AND URODYNAMICS, Vol. 34, Iss. 5, 2015-06 ,pp. : 438-443

John Wiley & Sons Inc

Access to resources Recommend Favorite